VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LGND
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LGNDLigand Pharmaceuticals Incorporated
$293.81$6.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLGNDBalance Sheet

Ligand Pharmaceuticals Incorporated (LGND) Balance Sheet

30Y historyFree accessUpdated daily

Total debt climbed from $5.7M in Q2 2025 to $1.2B in Q3 2026 and debt-to-equity rose to 1.20, while cash fell to $56.0M, indicating that acquisition-driven leverage now dominates a thinner liquidity cushion.

Income StatementBalance SheetCash FlowRatios

LGND Balance Sheet

Annual statement

LGND Balance Sheet

Ligand Pharmaceuticals Incorporated (LGND) balance sheet — 30-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Total Current Assets608.23M832.27M331.56M237.43M263.6M464.75M500.56M1.12B870.54M237.02M163.05M215.57M185.16M24.88M23.82M32.23M37.02M68.17M93.93M109.94M235.56M132.97M172.82M130.16M83.75M53.57M44.65M56.7M78M84.1M85.4M
Cash & Short-Term Investments447.39M733.52M256.17M170.31M211.87M341.11M411.19M1.07B764.57M201.66M141.05M200.22M167.34M15.98M12.38M17.04M22.7M53.23M80.67M94.41M171.85M86.93M112.49M99.03M64.25M37.69M23.66M47.2M32.8M62.3M34.8M
Cash Only55.96M174.93M72.31M22.95M45.01M19.52M47.62M71.54M718.38M201.66M141.05M200.22M167.34M15.98M12.38M7.04M3.35M16.03M28.75M76.81M158.4M66.76M92.31M59.03M42.42M20.74M9.22M29.9M32.8M62.3M34.8M
Short-Term Investments391.44M558.59M183.86M147.35M166.86M321.59M363.57M998.32M46.19M00000010M19.35M37.2M51.92M17.6M13.45M20.17M20.18M40M21.82M16.95M14.44M17.3M000
Accounts Receivable107.52M61.05M42.45M39.31M35.04M91.65M59.06M41.75M55.85M25.6M18.22M11.68M13.64M6.72M8.94M12.43M13.74M10.4M12.1M14.3M15.59M20.95M30.85M19.05M7.36M9.8M12.82M1.7M003.1M
Days Sales Outstanding105.4383.1292.7109.2765.17138.49131.81126.6981.0766.2161.0259.377.1550.11103.98151.09213.1397.48161.69404.9140.3643.3168.8649.2727.7846.8597.2915.17--30.75
Inventory14.51M9.13M14.11M23.97M13.29M27.33M26.49M7.3M7.12M4.37M1.92M1.63M269K1.39M1.7M1.3M-22.7M-53.23M1.15M-10.47M3.86M9.33M11.77M8.26M4.84M3.76M5.65M5.7M6.2M00
Days Inventory Outstanding-238.43505.65465.2249.6191.85160.42317.82234.69410.33297.46125.99102.6410.7588.62172.0196.73----62.1685.49107.9595.3887.0298.31.27K671.13-293.9--
Other Current Assets38.81M28.58M16.9M2.66M2.27M4.67M3.82M4.73M89.19M5.39M004.08M02K237K5.29M4.53M11K5.07M42.82M15.75M17.71M3.81M7.31M2.33M2.51M2.1M39M21.8M47.5M
Total Non-Current Assets1.63B728.37M610.22M549.79M499.07M832.84M861.73M371.27M390.26M434M438.53M318.36M72.87M79.83M80.44M90.12M38.54M45.53M77.52M63.34M90.5M181.65M159.64M171.1M186.86M63.9M68.77M77.9M78M23.3M16.7M
Property, Plant & Equipment24.22M10.79M24.81M25.06M27.49M32.6M37.17M17.62M5.37M4.21M1.82M372K486K867K788K455K559K8.52M12.9M2.87M5.55M22.48M23.65M23.5M9.67M9.69M10.97M20.5M23.7M14.9M11.7M
Fixed Asset Turnover19.63x24.84x6.74x5.24x7.14x7.41x4.40x6.83x46.81x33.50x59.91x193.32x132.79x56.49x39.83x66.02x42.11x4.57x2.12x4.50x25.39x7.86x6.91x6.01x9.99x7.88x4.38x2.00x0.75x3.47x3.15x
Goodwill207.86M101.54M105.25M103.37M105.67M105.67M189.66M95.23M306.44M314.54M276.91M60.59M62.96M65.34M12.24M14.89M005.38M000000000000
Intangible Assets302.04M422.31M266.65M299.61M352.64M386.8M606.31M230.54M31.46M19.53M25.82M8.55M4.57M4.57M55.91M57.44M12.95M2.52M0083.08M146.77M127.44M137.86M0000000
Long-Term Investments616.19M183.58M10.91M111.61M3M000601.22M6.44M8.35M29.73M-257K5.84M8.2M1.34M1.34M1.46M00000-250.12M18.05M000000
Other Non-Current Assets848.07M1.79M202.53M9.92M1.74M272.03M4.27M2.27M-600.75M4.86M1.74M2.55M4.86M1.64M3.29M15.76M23.32M7.97M59.24M60.47M1.86M12.4M8.55M9.74M159.13M54.21M57.8M57.4M54.3M8.4M5M
Total Assets2.24B1.56B941.77M787.22M762.67M1.3B1.36B1.49B1.26B671.02M601.59M533.93M258.03M104.71M104.26M122.35M75.56M113.7M171.45M173.28M326.05M314.62M332.47M301.25M270.61M117.47M113.42M134.6M156M107.4M102.1M
Asset Turnover0.14x0.17x0.18x0.17x0.26x0.19x0.12x0.08x0.20x0.21x0.18x0.13x0.25x0.47x0.30x0.25x0.31x0.34x0.16x0.07x0.43x0.56x0.49x0.47x0.36x0.65x0.42x0.30x0.11x0.48x0.36x
Asset Growth %316.87%65.71%19.63%3.22%-41.22%-4.75%-8.87%18.57%87.89%11.54%12.67%106.93%146.42%0.43%-14.79%61.93%-33.54%-33.68%-1.06%-46.86%3.63%-5.37%10.36%11.32%130.36%3.57%-15.73%-13.72%45.25%5.19%9.08%
Total Current Liabilities500.57M37.45M37.11M16.78M98.81M41.66M100.11M17M82.25M238.87M227.13M20.84M22.78M28.94M35.44M43.64M35.63M52.17M70.61M50.97M170.81M235.21M216.71M54.05M30.54M31.73M28.41M20.7M26.9M21.7M13.8M
Accounts Payable4.09M3.24M5.23M2.43M5.31M8.4M3.78M2.42M4.18M2.26M2.73M4.08M7.7M3.95M5.85M11.06M8.6M16.95M14.63M12.68M12.26M15.36M17.35M18.84M11.98M5.38M3.83M5.4M12.4M10.7M4.1M
Days Payables Outstanding-111.23179.41172.4825.2736.6749.3345.477.84240.93153.66179.13256.64307.55251.55593.37822.72-405.97--197.62140.7159.12217.5215.32140.93863.32635.81-587.79-398.52-159.2
Short-Term Debt448.31M00076.69M00026.43M224.53M212.91M201.99M334K9.11M14.84M16.2M8.03M01.83M1.53M37.75M2.75M2.92M2.48M2.09M5.37M3.48M4.1M3.2M2.8M2.6M
Deferred Revenue (Current)1.86M621K1.9M1.84M976K654K29.43M2.14M3.29M173K0-934K150K116K486K1.24M1.7M6.69M12.27M1.96M59.95M157.52M152.53M2.56M4.68M8.73M00000
Other Current Liabilities43.61M6.81M-3.2M4.94M6.26M22.57M49.38M7.62M44.3M1.41M5.09M15.04M12.63M12.26M10.88M13.34M5.3M14.18M18.72M10.47M14.35M00-105.66M-4.82M021.11M11.2M11.3M8.2M7.1M
Current Ratio1.22x22.23x8.93x14.15x2.67x11.15x5.00x66.09x10.58x0.99x0.72x10.35x8.13x0.86x0.67x0.74x1.04x1.31x1.33x2.16x1.38x0.57x0.80x2.41x2.74x1.69x1.57x2.74x2.90x3.88x6.19x
Quick Ratio1.19x21.98x8.55x12.72x2.53x10.50x4.74x65.66x10.50x0.97x0.71x10.27x8.12x0.81x0.62x0.71x1.68x2.33x1.31x2.36x1.36x0.53x0.74x2.26x2.58x1.57x1.37x2.46x2.67x3.88x6.19x
Cash Conversion Cycle-21.77409.36385.42333.61120.35249.57404.22283.53250.47210.017.89-94.7-219.65-112.81-317.37-574.89-----95.1-11.917.69-72.86-100.524.21508.7650.49---
Total Non-Current Liabilities775.13M505.98M74.22M69.52M66.37M434.77M552.65M710.68M617.64M13.51M3.6M208.7M210.84M26.16M42.34M70.06M46.92M57.78M111.2M93.19M127.89M189.83M191.07M176.48M166.06M143.62M140.13M139.5M140.5M51.4M53.8M
Long-Term Debt679.91M446.19M000320.72M442.29M638.96M609.86M18.86M29.56M205.37M195.91M013.44M35.54M22.85M30.99M47.52M627K0166.75M167.09M167.41M155.25M136.76M131.71M136.7M90.5M51.4M54M
Capital Lease Obligations33.41M4.2M5.82M5.75M10.34M2.26M5.64M9.97M0000000005.28M2.18M02.16M3.43M4M2.64M0000000
Deferred Tax Liabilities119.27M52.61M32.52M31.62M30.61M30.86M64.6M32.94M51.97M-22.38M-357K02.79M1.1M725K2.52M372K0-16.82M0-2.55M-4.2M-4.51M9.84M0000000
Other Non-Current Liabilities51.39M2.97M35.88M17M25.38M80.94M40.12M28.82M7.78M-8.88M-25.96M3.33M10.06M22.98M25.8M28.53M21.15M16.31M21.39M92.57M125.73M19.65M15.47M6.43M10.81M6.86M8.43M2.8M50M0-200K
Total Liabilities1.28B543.42M111.33M86.3M165.18M476.43M652.76M727.68M699.89M252.37M230.73M229.54M233.62M55.1M77.78M113.7M82.55M109.95M181.81M144.16M298.7M425.04M407.78M230.53M196.59M175.35M168.55M160.2M167.4M73.1M67.6M
Total Debt1.15B451.49M7.11M6.17M87.75M324.39M456.41M650.18M636.3M224.53M212.91M205.37M196.24M9.11M28.28M51.74M30.89M40.87M4.01M2.15M39.91M172.92M174.02M172.53M157.34M142.13M135.18M140.8M93.7M54.2M56.6M
Net Debt1.1B276.56M-65.2M-16.79M42.74M304.86M408.8M578.64M-82.08M22.87M71.86M5.15M28.91M-6.87M15.9M44.7M27.54M24.83M-24.75M-74.66M-118.5M106.16M81.71M113.5M114.91M121.38M125.96M110.9M60.9M-8.1M21.8M
Debt / Equity1.20x0.44x0.01x0.01x0.15x0.40x0.64x0.85x1.13x0.54x0.57x0.67x8.04x0.18x1.07x5.98x-10.92x-0.07x1.46x--2.44x2.13x----1.58x1.64x
Debt / EBITDA41.28x5.58x0.56x0.13x1.89x2.10x6.97x0.76x3.57x2.81x3.86x6.86x8.81x0.52x8.57x24.73x---------------
Net Debt / EBITDA39.28x3.42x-5.16x-0.35x0.92x1.97x6.24x0.68x-0.46x0.29x1.30x0.17x1.30x-0.39x4.82x21.37x---------------
Interest Coverage10.32x33.71x1.83x98.04x21.02x4.68x1.05x23.29x4.59x6.02x1.71x2.32x4.26x7.70x0.37x0.10x-264.57x-35.56x-481.75x-71.73x-----------
Total Equity961.76M1.02B830.44M700.91M597.49M821.16M709.52M767.23M560.91M418.65M370.85M304.39M24.41M49.61M26.48M8.65M-6.99M3.74M-10.37M29.11M27.35M-110.42M-75.32M70.73M74.02M-57.88M-55.13M-25.6M-11.4M34.3M34.5M
Equity Growth %65.85%22.49%18.48%17.31%-27.24%15.73%-7.52%36.78%33.98%12.89%21.83%1147.1%-50.8%87.32%206.33%223.67%-286.73%136.12%-135.6%6.45%124.77%-46.61%-206.49%-4.44%227.89%-4.99%-115.33%-124.56%-133.24%-0.58%22.78%
Book Value per Share48.1850.1245.4039.4735.4247.6143.8438.8323.3117.8317.8014.341.142.391.330.44-0.360.20-0.651.782.04-8.95-6.136.006.42-5.84-5.94-3.26-1.696.217.19
Total Shareholders' Equity961.76M1.02B830.44M700.91M597.49M821.16M709.52M767.23M560.91M418.65M370.85M304.39M26.32M49.61M26.48M8.65M-6.99M3.74M-10.37M29.11M27.35M-110.42M-75.32M70.73M74.02M-57.88M-55.13M-25.6M-11.4M34.3M34.5M
Common Stock20K20K20K18K17K17K16K17K21K21K21K20K20K21K21K21K21K123K119K101K100K73K73K73K72K60K57K100K000
Retained Earnings554.77M608.09M498.98M503.02M450.86M449.09M391.95M400.11M-229.2M-400.92M-431.13M-402.01M-659.32M-671.34M-682.76M-681.77M-691.95M-681.57M-679.63M-581.51M-862.8M-831.06M-794.66M-655.78M-618.32M-585.72M-542.73M-470.3M-395.6M-277.7M-177.6M
Treasury Stock00000000000000-42.28M-42.28M-42.23M-42.13M-42.13M-40.52M-911K-911K-911K-911K-911K-911K-911K0000
Accumulated OCI3.44M8.46M-5.94M-817K-984K-917K-801K-216K-1.02M2.49M2.74M4.9M4.95M2.91M-4.88M031K513K81K9K-481K490K229K-66K-43K-678K-2.03M-4.1M-17.8M-14.5M-11M
Minority Interest000000000000-1.91M000000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetMixed
Cash FlowMixed
Top Statement Risk

Acquisition-driven balance sheet swing

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Balance Sheet Rebuilt Through Acquisition Leverage

According to reported quarterly figures, LGND's total assets rose from $948.6M in Q2 2025 to $2.2B in Q3 2026 while total debt climbed from $5.7M to $1.2B, a rapid expansion that reshaped the balance sheet within roughly one year.

The step-change in both assets and debt suggests the company financed a large acquisition largely through borrowing rather than retained earnings, which appears consistent with the $836.3M net acquisition outflow in Q3 2026. Equity grew more modestly, so the expansion is increasingly reliant on lenders, and investors should monitor whether royalty cash flows can service the higher debt load without further strain.

Leverage Rises Sharply After Acquisition Funding

Based on reported figures, LGND's debt-to-equity ratio moved from 0.01 in mid-2025 to 1.20 in Q3 2026, indicating that leverage has become a dominant feature of the capital structure rather than a minor one.

A D/E ratio near 1.2 changes the risk profile of the equity, since interest obligations now compete directly with operating overhead that already consumes much of the gross royalty margin. The figures do not disclose maturity profiles or covenant terms, so refinancing risk cannot be fully assessed from this data alone and warrants further investigation.

Cash Buffer Thins Against Rising Obligations

As reported in financial statements, LGND's cash fell to $56.0M in Q3 2026 from $1.0B in Q2 2026, while the current ratio stood at 1.22, leaving a narrower cushion relative to near-term obligations.

The sharp drawdown in cash after the acquisition implies the balance sheet's liquidity was largely deployed rather than held in reserve, which reduces flexibility to absorb royalty volatility. A current ratio of 1.22 is adequate on paper, yet the swing from very high to thin cash coverage suggests the buffer against shocks has been materially reduced.

Goodwill and Intangibles Drive Asset Base

Per reported figures, goodwill of $207.9M and PPE of only $24.2M in Q3 2026 indicate that LGND's asset base is overwhelmingly intangible, consistent with an asset-light royalty aggregator model.

A small PPE balance alongside a large acquisition-driven asset base confirms that value rests on purchased royalty streams and intellectual property rather than physical plant. This makes asset valuation sensitive to impairment testing, and the gap between the $2.2B asset base and the much smaller tangible base warrants monitoring if royalty performance underperforms acquisition assumptions.

Headline Equity Masks Negative Operating Quarter

Based on the supplied data, LGND's retained earnings of $554.8M and a reported Q3 2026 operating loss of $15.8M suggest that the equity base may look stronger than the most recent operating trend supports.

Retained earnings built up over prior profitable periods can mask a near-term reversal in earnings power, particularly when non-operating items drive reported net income. Investors should consider that the balance sheet's apparent solidity depends partly on historical accumulation rather than current operating momentum, and that the royalty concentration noted in prior analysis could amplify any further decline.

LGND — Frequently Asked Questions

Quick answers to the most common questions about buying LGND stock.

What are the total assets of Ligand Pharmaceuticals Incorporated (LGND)?

As of 2025, Ligand Pharmaceuticals Incorporated (LGND) had total assets of $1.56B including $832.3M in current assets.

How much debt does Ligand Pharmaceuticals Incorporated (LGND) have?

Ligand Pharmaceuticals Incorporated (LGND) carries total debt of $451.5M, offset by $733.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Ligand Pharmaceuticals Incorporated?

Ligand Pharmaceuticals Incorporated (LGND) has total shareholders' equity (book value) of $1.02B ($50.12 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Ligand Pharmaceuticals Incorporated's current ratio and liquidity?

Ligand Pharmaceuticals Incorporated (LGND) reported a current ratio of 22.23x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.